Wird geladen...

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial

OBJECTIVES: Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48. METHODS: Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were randomized 1:1 to maraviroc with darunavir/ritonavir qd (...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS One
Hauptverfasser: Rossetti, Barbara, Gagliardini, Roberta, Meini, Genny, Sterrantino, Gaetana, Colangeli, Vincenzo, Re, Maria Carla, Latini, Alessandra, Colafigli, Manuela, Vignale, Francesca, Rusconi, Stefano, Micheli, Valeria, Di Biagio, Antonio, Orofino, Giancarlo, Ghisetti, Valeria, Fantauzzi, Alessandra, Vullo, Vincenzo, Grima, Pierfrancesco, Francisci, Daniela, Mastroianni, Claudio, Antinori, Andrea, Trezzi, Michele, Lisi, Lucia, Navarra, Pierluigi, Canovari, Benedetta, D’Arminio Monforte, Antonella, Lamonica, Silvia, D’Avino, Alessandro, Zazzi, Maurizio, Di Giambenedetto, Simona, De Luca, Andrea
Format: Artigo
Sprache:Inglês
Veröffentlicht: Public Library of Science 2017
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5697828/
https://ncbi.nlm.nih.gov/pubmed/29161288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0187393
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!